Inhalable Biologics Market Size & Share 2025 - 2034

Inhalable Biologics Market Size

The global inhalable biologics market was estimated at USD 3.8 billion in 2024. The market is expected to grow from USD 4.3 billion in 2025 to USD 17.4 billion in 2034, growing at a CAGR of 16.7%. The rising prevalence of chronic and acute respiratory disorders, such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, and pulmonary infections, is stimulating the demand for inhalable biologics.

For instance, according to the WHO, COPD is the fourth leading cause of death worldwide, causing approximately 5% of all global deaths in 2021, that is about 3.5 million deaths. Such a high prevalence of chronic and infectious diseases affecting the respiratory system increases the demand for effective inhalable biologics.
 

Inhalable biologics offer targeted delivery, faster onset of action, and improved patient adherence compared to traditional injectable biologics. The increasing respiratory diseases, with chronic respiratory conditions, are the top causes of death globally, highlighting the importance of innovative treatments. According to the World Health Organization, every year, more than 13% or 7.7 million people die from respiratory diseases globally.
 

Additionally, NIH mentions that chronic respiratory diseases are the third leading cause of death and about 4 million people die of it. Both the acute and chronic respiratory conditions are rising due to factors such as pollution, aging populations, tobacco usage and genetics, that accelerate the need for effective treatment solutions. Moreover, global health organizations are supporting inhalable drugs delivery through regulatory policies, government initiatives, and heavy investment in research and development. Regulatory agencies such as the U.S. Food and Drug Administration and European Medicines Agency have concentrated on approvals for inhaled biologics to address unmet clinical needs. The public sector partnerships with biopharmaceutical companies further support affordable biologics. All these factors combined will offer lucrative growth opportunities in the market.
 

Inhalable biologics market focuses on the development, manufacturing and distribution of biologic therapies intended for pulmonary/respiratory administration. These utilizes devices such as dry powder inhalers, nebulizers, soft mist inhalers, and metered dose inhalers. Inhalable biologics are used to treat a variety of chronic and acute conditions, especially affecting the respiratory system, by enhancing targeted delivery and reducing side effects. As the prevalence of chronic diseases rises and demand increases for patient-centric treatments, the market is expected to expand globally.
 

Inhalable Biologics Market Trends

• The growth of the market is significantly stimulated by advanced technologies such as smart drug delivery systems, rising consumer awareness, and innovations in formulations.
   
• The rising prevalence of diseases such as asthma, COPD, and pulmonary arterial hypertension has increased pressure on the healthcare systems to develop faster, more targeted, and effective treatment options.
• Inhalable biologics are used into respiratory care protocols, due to direct delivery to the lungs, reduced systemic exposure, especially in paediatric and geriatric populations.
   
• Additionally, the trend of development of inhaled monoclonal antibodies is stimulating the market growth. Biopharmaceutical companies are shifting towards pulmonary-based biologics that can help in local inflammation and immune responses. Inhaled formulations such as IL-4 or IL-13 and IgE inhibitors are used in respiratory delivery, improving therapeutic results in diseases. Such innovations minimize side effects and increase drug bioavailability.
   
• The market is witnessing continuous innovation in inhaler technology, including smart inhalers, dry powder inhalers (DPIs), and nebulizer systems optimized for biologic delivery. These advancements ensure better control over dosage, particle size distribution, and delivery to targeted lung regions.
   
• Similarly, smart inhalers with sensors for real-time tracking of medication adherence and usage patterns is beneficial for chronic respiratory conditions. Additionally, integration with mobile health applications helps in remote patient monitoring, enabling healthcare providers to make data-driven adjustments for treatment plans and reduce hospital visits.
   
• Moreover, increasing research in dry form of biologics and nanoparticle delivery systems is stimulating stability and shelf-life of inhalable biologics. The traditional liquid biologics that require refrigeration can be changed by utilising new dry formulations that are easy to store and transport, improving accessibility in remote areas. This is relevant for national health programs to distribute biologics in rural populations with undeveloped medical infrastructure.
   
• Lastly, strategic collaborations and licensing deals are playing a crucial role in the growth of the market. Biotech firms developing novel biologics are partnering with device manufacturers to overcome delivery and formulation challenges. These alliances help accelerate clinical development, expand market reach, and enable co-development of advanced drug-device combinations such as smart inhalers. Licensing agreements also allow smaller companies to leverage the commercialization and regulatory expertise of larger players, driving innovation and faster market entry.
   

Inhalable Biologics Market Analysis

Based on the product type, the global market is divided into proteins and peptides, vaccines, and monoclonal antibodies. The proteins and peptides segment dominated the market in 2024 and was valued at USD 1.9 billion.
 

• Proteins and peptides have high potency, specificity, and biological activity for inhalation delivery, which are non-invasive options instead of traditional injections. In addition, the rapid onset of action and localized treatment benefits offered by these products stimulate the demand for inhalable proteins and peptides targeting several diseases.
   
• Moreover, proteins and peptides have a good therapeutic effect in treating a range of chronic diseases, especially respiratory and metabolic disorders, which stimulates the market growth. These biomolecules are important for targeting conditions such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis.
   
• Furthermore, the increasing prevalence of respiratory diseases is a prominent factor for the use of proteins and peptides. Increasing population and urban pollution levels escalate the demand for effective and patient-friendly solutions. Inhalable biologics, particularly proteins and peptides, provide high efficacy and reduced side effects, thus increasing the demand for these products.

Learn more about the key segments shaping this market

Download Free PDF

• The high global prevalence of respiratory diseases stimulates the demand for effective inhalable biologics. Diseases such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis affect millions of people globally, which places a burden on healthcare systems.
   
• The targeted approach of inhalable biologics directly to the site of inflammation in the lungs increases drug efficacy along with reduction of side effects, which is critical in managing long-term respiratory conditions.
• Additionally, technological advancements such as innovative drug delivery systems, which include dry powder inhalers, metered-dose inhalers, and advanced nebulizers, that directly deliver the drug in the respiratory system, further drive the segmental growth.
   
• Furthermore, several investments and research in biologic therapies specifically targeting respiratory diseases will positively drive the market growth.
   
• The approved inhalable biologics have shown strong market performance, with several candidates participating in clinical trials for respiratory indications, which will further boost the market growth over the forecast years.
   

Based on the dosage form, the global inhalable biologics market is divided into dry powder inhalers, metered dose inhalers, nebulizers, and soft mist inhalers. The dry powder inhalers segment dominated the market in 2024 and is anticipated to witness growth at a CAGR of 17.1%.
 

• Dry powder inhalers (DPIs) hold a high market share in the market due to their superior stability profile, which makes them particularly suitable for delivering biologic therapies.
   
• Unlike liquid formulations that may require cold chain logistics, DPIs enable the formulation of biologics in a dry state, enhancing shelf-life and eliminating the need for refrigeration. This is especially valuable for biopharmaceutical companies targeting global markets, including remote and low-resource regions where cold chain infrastructure may be limited.
   
• Furthermore, DPIs offer a user-friendly and portable alternative to nebulizers and metered-dose inhalers, improving patient compliance, especially for chronic conditions.
   
• The ability to achieve deep lung deposition of therapeutic biologics, such as monoclonal antibodies, vaccines, and peptides, further enhances their therapeutic potential and supports their widespread adoption.
   

Based on the distribution channel, the global inhalable biologics market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2024 and is expected to reach USD 8.8 billion by 2034.
 

• Hospital pharmacies hold a significant market share in the inhalable biologics sector due to their centralized role in managing and dispensing specialized therapies.
   
• Inhalable biologics, which require careful handling, dosing precision, and patient monitoring, are often administered in hospital settings under medical supervision.
   
• Hospital pharmacies are well-equipped with the infrastructure and skilled personnel to manage these complex therapies, ensuring patient safety and adherence to protocols, which drives their dominant presence in the market.

• The market is stimulated by the rising prevalence of respiratory diseases and increased spending on non-invasive therapeutic solutions.
   
• Advancements in inhalation drug delivery technology and a growing focus on targeted and efficient treatment approaches also support market growth.
   

The U.S. market was valued at USD 0.9 billion and USD 1 billion in 2021 and 2022, respectively. The market size reached USD 1.4 billion in 2024, growing from USD 1.2 billion in 2023.
 

• The increasing level of pollution in the U.S. is contributing to an increase in respiratory issues such as nasal congestion, asthma, and allergies.
   
• According to the CDC, 25.7% of adults have seasonal allergies. Additionally, the Asthma and Allergy Foundation of America states that 1 out of 12 adults suffers from asthma.  
   
• Growing awareness among U.S. consumers about the risk factors caused by air pollution and its impact on respiratory health drives the market growth. This rising awareness is stimulating the demand for biologics as more consumers prefer preventive measures.
   
• Additionally, the U.S. FDA has played a role in stimulating the development and approval of inhalable biologics. The FDA's regulations, along with programs such as the Orphan Drug Designation, have escalated the market of inhalable therapies in the country.
   

Europe inhalable biologics market accounted for USD 963.9 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Rising awareness and adoption of inhalable biologic therapies in the region, along with increasing government initiatives to improve respiratory care and chronic disease management, are anticipated to spur growth in the market.
   
• Moreover, advancements in drug delivery technologies, such as dry powder inhalers and nanoparticle-based formulations, along with the introduction of patient-friendly and cost-effective inhalable biologic solutions, boost the requirement of the inhalable biologics in the Europe region.
   
• Also, the presence of key market players in the region strengthens the market growth. These companies actively participate in innovation through the development of next-generation inhalable biologics, expanded therapeutic coverage, and partnerships with public health agencies, thereby advancing market growth.
   

Germany inhalable biologics market is anticipated to witness considerable growth over the analysis period.
 

• The rising prevalence of chronic diseases such as diabetes and respiratory issues has resulted in higher demand for inhalable biologics, which provide non-invasive treatment to the patients.
   
• In 2024, Germany saw a persistently high burden of acute respiratory infections (ARIs) requiring hospitalization, with a peak of 602 cases per day in November 2023. Further, according to Deutsche Zentren der Gesundheitsforschung, 8.5 million people suffer from diabetes, and about 2 million people live with undiagnosed diabetes in Germany. Such a high prevalence of respiratory and metabolic disorders increases the demand for effective therapeutics.
   
• Further, the integration of inhalable biologics into public health insurance programs and guidelines stimulates the market growth. This enables a more predictable distribution of high-cost inhalable therapies.
   

The Asia Pacific inhalable biologics market is anticipated to grow at the highest CAGR of 17.2% during the analysis timeframe.
 

• The market in the Asia Pacific region is growing rapidly due to the rise in respiratory and chronic disease cases, increasing public health awareness, and the improvement of healthcare infrastructure across both urban and rural populations.
   
• Countries such as China, India, and Japan are adopting inhalable biologics at a faster rate due to the enhanced demand for innovative therapies, government-led healthcare initiatives, and the rise in hospital-based treatment programs targeting chronic conditions.
   
• Additionally, the rapid rise in the number of public health clinics and specialty care centers, along with government policies aimed at expanding access to advanced therapies and integrating inhalable biologics into national health programs, contributes to the rapid growth of the market in the region.
   

China inhalable biologics market is estimated to grow with a significant CAGR, making it the fastest growing country in the Asia Pacific market.
 

• With the rising urbanization, industrial pollution, and tobacco utilisation, chronic respiratory conditions such as asthma and COPD have been a growing health concern in the country.
   
• According to the WHO, COPD alone affects over 100 million people in China, that is almost 25% of the overall global cases. This is creating a strong need for effective therapeutic options.
   
• In addition, the strategic investment in biopharmaceutical innovation and healthcare infrastructure by the government further stimulates the market. The Healthy China 2030 initiative prioritizes respiratory health and domestic drug manufacturing, encouraging local companies to develop cost-effective inhalable biologics.
   
• Moreover, China's pharmaceutical industry is attracting funding from both international and domestic firms and collaborating to create inhalable biologics, which will further boost the market growth over the forecast years.
   

Brazil leads the Latin American inhalable biologics market, with remarkable growth during the analysis period.
 

• Brazil has a high burden of respiratory diseases.
   
• For example, respiratory conditions such as asthma and chronic bronchitis are among the top causes of hospitalizations in the country, especially affecting children and elderly populations.
   
• According to Sage Journals, COPD is sixth sixth-ranking cause of death in Brazil with a prevalence of 15.8%. Additionally, NIH states that asthma is the 4^th leading cause of hospitalization in the country, which together stimulates the market for inhalable biologics.
   
• Additionally, the presence of both local and international biopharmaceutical companies in the country further drives the market growth.
   

Saudi Arabia is to experience the highest growth rate in the Middle East and Africa inhalable biologics market.
 

• The increasing incidence of respiratory illnesses such as asthma and chronic obstructive pulmonary disease (COPD), coupled with the government's dedication to enhancing public health, is escalating the need for innovative treatments.
   
• Inhalable biologics are gaining popularity in the country, as more consumers look for non-invasive solutions to cope with the effects, thus escalating market expansion.
   

Inhalable Biologics Market Share

Competition in the inhalable biologics industry is marked by well-established companies, emerging firms, and local players fighting to capture a larger share of the market. The top 4 players such as AstraZeneca, F-Hoffman Roche, Teva Pharmaceutical, and Boehringer Ingelheim, account for approximately 60% of the global market. These key players focus on various strategies such as acquisitions, business expansion, and novel product launches to consolidate their market presence.
 

Additionally, there are several local and regional players operating in the market who are boosting competition by providing affordable options at lower costs. These players are also involved in several growth strategies to boost their market share.
 

Inhalable Biologics Market Companies

Few prominent players operating in the inhalable biologics industry includes:

• AbbVie
• AstraZeneca
• Boehringer Ingelheim
• CanSino Biologics
• Chiesi Pharmaceuticals
• F-Hoffman Roche
• Kamada Pharmaceuticals
• Mannkind
• Merxin
• Teva Pharmaceutical
• United Therapeutics
   
• AstraZeneca is a key player in the market, leveraging its strong respiratory portfolio and advanced drug delivery technologies. The company focuses on developing inhalable treatments for chronic respiratory diseases such as asthma and COPD, enhancing patient convenience and adherence. In May 2025, AstraZeneca’s Trixeo Aerosphere was approved in the UK as inhaled respiratory medicine using a next-generation propellant with almost zero global warming potential. The updated formulation demonstrated bioequivalence to the previous version and maintained its safety profile.
   
• MannKind is a key player in the market, known for its innovative dry powder formulation technology. Its flagship product, Afrezza, delivers rapid-acting insulin via inhalation, offering a needle-free alternative for diabetes management and improving patient adherence.
   

Inhalable Biologics Industry News

• In June 2025, Intertek expanded pharmaceutical GMP laboratory in Melbourn, UK, to enhance support for inhaled and nasal biologics development, including mRNA and nucleotide-based therapeutics. This facility upgrade strengthens Intertek’s biologics testing capabilities and accelerates drug development timelines.
   
• In January 2025, Iconovo and Lonza collaborated to develop spray-dried formulations of an intranasal biologic targeting obesity, designed for use with ICOone nasal device. The focus is on optimizing particle size and stability, along with device compatibility. This effort aims to replace injectable treatments.
   
• In December 2024, MannKind has received approval for Afrezza inhalation powder for adults with diabetes from India’s CDSCO. This approval brings the first inhaled insulin option to the world’s second-largest diabetes population.
   
• In March 2023, Stevanato partnered with Resyca for the development and manufacturing of pre-fillable glass syringes integrated with Resyca’s soft mist inhaler technology for inhalation of biological products. This partnership provided an inhalation solution for novel inhaled biologics.
   

The inhalable biologics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Proteins and peptides
• Vaccines
• Monoclonal antibodies

Market, By Application

• Respiratory diseases
• Infectious diseases
• Diabetes

Market, By Dosage Form

• Dry powder inhalers
• Metered dose inhalers
• Nebulizers
• Soft mist inhalers

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE